Dopaminergic drugs in type 2 diabetes and glucose homeostasis

Pharmacological Research

Volumn 109, Issue , 2016, Pages 74-80

  Lopez Vicchi, Felicitas ^a   Luque, Guillermina Maria ^a   Brie, Belen ^a   Nogueira, Juan Patricio ^b   Garcia Tornadu, Isabel ^a   Becu Villalobos, Damasia ^a  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b Universidad Nacional de Formosa   (Argentina)

Author keywords

Bromocriptine; Dopamine; Food intake; Glucose; Insulin; Pancreas; Pituitary; Sulpiride

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; METFORMIN; NEUROLEPTIC AGENT; NORADRENALIN; SULFONYLUREA DERIVATIVE; GLUCOSE;

ACROMEGALY; BIOLOGICAL RHYTHM; BIPOLAR DISORDER; DEPRESSIVE PSYCHOSIS; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DOPAMINE RELEASE; FOOD INTAKE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; HYPOTENSION; INSULIN RELEASE; INSULIN RESISTANCE; LIPOGENESIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; SCHIZOPHRENIA; SUPRACHIASMATIC NUCLEUS; VOMITING; ANIMAL; DIABETES MELLITUS, TYPE 2; GENETICS; HOMEOSTASIS; METABOLISM;

ACROMEGALY; ANIMALS; BROMOCRIPTINE; DIABETES MELLITUS, TYPE 2; DOPAMINE AGENTS; GLUCOSE; HOMEOSTASIS; HUMANS; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PROLACTINOMA; RECEPTORS, DOPAMINE D2;

EID: 84953439344     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.12.029     Document Type: Review

References (97)

1. W. Li, P.T. Katzmarzyk, R. Horswell, Y. Wang, J. Johnson, and G. Hu HbA1c and all-cause mortality risk among patients with type 2 diabetes Int. J. Cardiol. 202 2016 490 496
2. C. Missale, S.R. Nash, S.W. Robinson, M. Jaber, and M.G. Caron Dopamine receptors: from structure to function Physiol. Rev. 78 1998 189 225
3. I. Garcia-Tornadu, M.I. Perez-Millan, V. Recouvreux, M.C. Ramirez, G. Luque, G.S. Risso, and et al. New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2 mouse Neuroendocrinology 92 2010 207 214
4. D. Noain, M.I. Perez-Millan, E.P. Bello, G.M. Luque, C.R. Casas, D.M. Gelman, and et al. Central dopamine D2 receptors regulate growth-hormone-dependent body growth and pheromone signaling to conspecific males J. Neurosci. 33 2013 5834 5842
5. D. Guivarc'h, P. Vernier, and J.D. Vincent Sex steroid hormones change the differential distribution of the isoforms of the D2 dopamine receptor messenger RNA in the rat brain Neuroscience 69 1995 159 166
6. N. Ben Jonathan, and R. Hnasko Dopamine as a prolactin (PRL) inhibitor Endocr. Rev. 22 2001 724 763
7. B. Rubi, S. Ljubicic, S. Pournourmohammadi, S. Carobbio, M. Armanet, C. Bartley, and et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion J. Biol. Chem. 280 2005 36824 36832
8. I. Garcia-Tornadu, A.M. Ornstein, A. Chamson-Reig, M.B. Wheeler, D.J. Hill, E. Arany, and et al. Disruption of the dopamine D2 receptor impairs insulin secretion and causes glucose intolerance Endocrinology 151 2010 1441 1450
9. A.H. Barnett, C. Chapman, K. Gailer, and C.J. Hayter Effect of bromocriptine on maturity onset diabetes Postgrad. Med. J. 56 1980 11 14
10. M.O. Sowell, N. Mukhopadhyay, P. Cavazzoni, S. Shankar, H.O. Steinberg, A. Breier, and et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo J. Clin. Endocrinol. Metab. 87 2002 2918 2923
11. H. Pijl Reduced dopaminergic tone in hypothalamic neural circuits: expression of a thrifty genotype underlying the metabolic syndrome? Eur. J. Pharmacol. 480 2003 125 131
12. L. Citrome, A. Jaffe, J. Levine, B. Allingham, and J. Robinson Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients Psychiatr. Serv. 55 2004 1006 1013
13. S.R. Marder, S.M. Essock, A.L. Miller, R.W. Buchanan, D.E. Casey, J.M. Davis, and et al. Physical health monitoring of patients with schizophrenia Am. J. Psychiatry 161 2004 1334 1349
14. M. De Hert, J. Detraux, R. van Winkel, W. Yu, and C.U. Correll Metabolic and cardiovascular adverse effects associated with antipsychotic drugs Nat. Rev. Endocrinol. 8 2012 114 126
15. H.E. Lebovitz Metabolic consequences of atypical antipsychotic drugs Psychiatr. Q. 74 2003 277 290
16. J.E. de Leeuw van Weenen, E.T. Parlevliet, J.P. Schroder-van der Elst, S.A. van den Berg, K. Willems van Dijk, J.A. Romijn, and et al. Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice Exp. Diabetes Res. 2011 2011 928523
17. L. Brunerova, J. Potockova, J. Horacek, J. Suchy, and M. Andel Central dopaminergic activity influences metabolic parameters in healthy men Neuroendocrinology 97 2013 132 138
18. G. Rosati, M. Maioli, I. Aiello, A. Farris, and V. Agnetti Effects of long-term l-DOPA therapy on carbohydrate metabolism in patients with Parkinson's disease Eur. Neurol. 14 1976 229 239
19. H. Pijl, S. Ohashi, M. Matsuda, Y. Miyazaki, A. Mahankali, V. Kumar, and et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes Diabetes Care 23 2000 1154 1161
20. L.E. Ericson, R. Hakanson, and I. Lundquist Accumulation of dopamine in mouse pancreatic B-cells following injection of l-DOPA. Localization to secretory granules and inhibition of insulin secretion Diabetologia 13 1977 117 124
21. R.T. Zern, J.L. Bird, and J.M. Feldman Effect of increased pancreatic islet norepinephrine, dopamine and serotonin concentration on insulin secretion in the golden hamster Diabetologia 18 1980 341 346
22. T. Baptista, A. Lacruz, X. Paez, L. Hernandez, and S. Beaulieu The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved? Eur. J. Pharmacol. 447 2002 91 98
23. B. Ahren Autonomic regulation of islet hormone secretion - implications for health and disease Diabetologia 43 2000 393 410
24. M.J. Garcia Barrado, M.C. Iglesias Osma, E.J. Blanco, H.M. Carretero, R.V. Sanchez, I.L. Catalano, and et al. Dopamine modulates insulin release and is involved in the survival of rat pancreatic beta cells PLoS One 10 2015 e0123197
25. 2+ efflux by dopamine in glucose-stimulated pancreatic islets Gen. Pharmacol. 25 1994 909 916
26. E. Shankar, K.T. Santhosh, and C.S. Paulose Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro IUBMB Life 58 2006 157 163
27. A. Ustione, D.W. Piston, and P.E. Harris Minireview dopaminergic regulation of insulin secretion from the pancreatic islet Mol. Endocrinol. 27 2013 1198 1207
28. E.S. Di Cairano, S. Moretti, P. Marciani, V.F. Sacchi, M. Castagna, A. Davalli, and et al. Neurotransmitters and neuropeptides: new players in the control of islet of Langerhans' cell mass and function J. Cell. Physiol. 231 2016 756 767
29. W. Wu, J. Shang, Y. Feng, C.M. Thompson, S. Horwitz, J.R. Thompson, and et al. Identification of glucose-dependant insulin secretion targets in pancreatic beta cells by combining defined-mechanism compound library screening and siRNA gene silencing J. Biomol. Screen. 13 2008 128 134
30. T. Shimazu, M. Noma, and M. Saito Chronic infusion of norepinephrine into the ventromedial hypothalamus induces obesity in rats Brain Res. 369 1986 215 223
31. G.A. Smythe, H.S. Grunstein, J.E. Bradshaw, M.V. Nicholson, and P.J. Compton Relationships between brain noradrenergic activity and blood glucose Nature 308 1984 65 67
32. S. Luo, A.H. Meier, and A.H. Cincotta Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters Neuroendocrinology 68 1998 1 10
33. S. Luo, J. Luo, A.H. Meier, and A.H. Cincotta Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance Neuroreport 8 1997 3495 3499
34. R.D. Palmiter Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci. 30 2007 375 381
35. J.H. Baik Dopamine signaling in food addiction: role of dopamine D2 receptors BMB Rep. 46 2013 519 526
36. G.J. Wang, N.D. Volkow, J. Logan, N.R. Pappas, C.T. Wong, W. Zhu, and et al. Brain dopamine and obesity Lancet 357 2001 354 357
37. S.O. Fetissov, and M.M. Meguid On dopamine, D2 receptor, and Taq1A polymorphism in obesity and anorexia Nutrition 25 2009 132 133
38. C.L. Roth, A. Hinney, E.A. Schur, C.T. Elfers, and T. Reinehr Association analyses for dopamine receptor gene polymorphisms and weight status in a longitudinal analysis in obese children before and after lifestyle intervention BMC Pediatr. 13 2013 197
39. A.W. Bergen, M. Yeager, R.A. Welch, K. Haque, J.K. Ganjei, M.B. van den Bree, and et al. Association of multiple DRD2 polymorphisms with anorexia nervosa Neuropsychopharmacology 30 2005 1703 1710
40. K.E. Steele, G.P. Prokopowicz, M.A. Schweitzer, T.H. Magunsuon, A.O. Lidor, H. Kuwabawa, and et al. Alterations of central dopamine receptors before and after gastric bypass surgery Obes. Surg. 20 2010 369 374
41. A.H. Meier, A.H. Cincotta, and W.C. Lovell Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics Experientia 48 1992 248 253
42. P.M. Johnson, and P.J. Kenny Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats Nat. Neurosci. 13 2010 635 641
43. A.H. Meier, and A.H. Cincotta Circadian rhythms regulate the expression of the thrifty genotype/phenotype Diabetes Rev. 4 1996 464 487
44. S. Luo, J. Luo, and A.H. Cincotta Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters Neuroreport 10 1999 2073 2077
45. A.H. Cincotta, T.A. MacEachern, and A.H. Meier Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters Am. J. Physiol. 264 1993 E285 E293
46. A.H. Cincotta, B.C. Schiller, and A.H. Meier Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus Metabolism 40 1991 639 644
47. A.H. Cincotta, and A.H. Meier Prolactin permits the expression of a circadian variation in lipogenic responsiveness to insulin in hepatocytes of the golden hamster (Mesocricetus auratus) J. Endocrinol. 106 1985 173 176
48. A.H. Cincotta, and A.H. Meier Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus) Metabolism 44 1995 1349 1355
49. E. Mezey, G. Eisenhofer, G. Harta, S. Hansson, L. Gould, B. Hunyady, and et al. A novel nonneuronal catecholaminergic system: exocrine pancreas synthesizes and releases dopamine Proc. Natl. Acad. Sci. U. S. A. 93 1996 10377 10382
50. L.W. Swanson, and P.E. Sawchenko Paraventricular nucleus: a site for the integration of neuroendocrine and autonomic mechanisms Neuroendocrinology 31 1980 410 417
51. B.J. Davis, and P.H. Smith Effects of substantia nigra lesions on the volumes of A, B, and D cells and the content of insulin and glucagon in the rat pancreas Diabetologia 28 1985 756 762
52. J. Lang Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion Eur. J. Biochem. 259 1999 3 17
53. A. Maffei, A.M. Segal, J.C. Alvarez-Perez, A. Garcia-Ocana, and P.E. Harris Anti-incretin, anti-proliferative action of dopamine on beta-cells Mol. Endocrinol. 29 2015 542 557
54. N. Ben Jonathan, and E. Hugo Prolactin (PRL) in adipose tissue: regulation and functions Adv. Exp. Med. Biol. 846 2015 1 35
55. B. Woodside Prolactin and the hyperphagia of lactation Physiol. Behav. 91 2007 375 382
56. M.C. Garcia, M. Lopez, O. Gualillo, L.M. Seoane, C. Dieguez, and R.M. Senaris Hypothalamic levels of NPY, MCH, and prepro-orexin mRNA during pregnancy and lactation in the rat: role of prolactin FASEB J. 17 2003 1392 1400
57. L. Naef, and B. Woodside Prolactin/leptin interactions in the control of food intake in rats Endocrinology 148 2007 5977 5983
58. M.I. Perez Millan, G.M. Luque, M.C. Ramirez, D. Noain, A.M. Ornstein, M. Rubinstein, and et al. Selective disruption of dopamine D2 receptors in pituitary lactotropes increases body weight and adiposity in female mice Endocrinology 155 2014 829 839
59. U.A. White, and J.M. Stephens Transcriptional factors that promote formation of white adipose tissue Mol. Cell. Endocrinol. 318 2010 10 14
60. C.A. Jaffe, and A.L. Barkan Treatment of acromegaly with dopamine agonists Endocrinol. Metab. Clin. N. Am. 21 1992 713 735
61. S. Luo, J. Luo, and A.H. Cincotta Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster Chronobiol. Int. 17 2000 155 172
62. S. Luo, Y. Liang, and A.H. Cincotta Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters Neuroendocrinology 69 1999 160 166
63. M. Ezrokhi, S. Luo, Y. Trubitsyna, and A.H. Cincotta Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats Diabetol. Metab. Syndr. 6 2014 104
64. A.H. Cincotta, A.H. Meier, and J.M. Cincotta Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes Expert Opin. Investig. Drugs 8 1999 1683 1707
65. A.H. Cincotta, A.H. Meier, and L.L. Southern Bromocriptine alters hormone rhythms and lipid metabolism in swine Ann. Nutr. Metab. 33 1989 305 314
66. A.F. Chintoh, S.W. Mann, L. Lam, A. Giacca, P. Fletcher, J. Nobrega, and et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model Schizophr. Res. 108 2009 127 133
67. S.E. Kahn, R.L. Hull, and K.M. Utzschneider Mechanisms linking obesity to insulin resistance and type 2 diabetes Nature 444 2006 840 846
68. F.M. Reis, A.M. Reis, and C.C. Coimbra Effects of hyperprolactinaemia on glucose tolerance and insulin release in male and female rats J. Endocrinol. 153 1997 423 428
69. M. Freemark, I. Avril, D. Fleenor, P. Driscoll, A. Petro, E. Opara, and et al. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance Endocrinology 143 2002 1378 1385
70. R.S. Brown, A.E. Herbison, and D.R. Grattan Effects of prolactin and lactation on A15 dopamine neurones in the rostral preoptic area of female mice J. Neuroendocrinol. 27 2015 708 717
71. L.E. Rojo, P.A. Gaspar, H. Silva, L. Risco, P. Arena, K. Cubillos-Robles, and et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology Pharmacol. Res. 101 2015 74 85
72. D.C. Henderson, and P.M. Doraiswamy Prolactin related and metabolic adverse effects of atypical antipsychotic agents J. Clin. Psychiatry 69 Suppl. 1 2008 32 44
73. I. Tarricone, M. Casoria, B.F. Gozzi, D. Grieco, M. Menchetti, A. Serretti, and et al. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre BMC Psychiatry 6 2006 11
74. J.S. Ballon, U. Pajvani, Z. Freyberg, R.L. Leibel, and J.A. Lieberman Molecular pathophysiology of metabolic effects of antipsychotic medications Trends Endocrinol. Metab. 25 2014 593 600
75. J.M. Amiel, C.V. Mangurian, R. Ganguli, and J.W. Newcomer Addressing cardiometabolic risk during treatment with antipsychotic medications Curr. Opin. Psychiatry 21 2008 613 618
76. J.W. Newcomer, D.W. Haupt, R. Fucetola, A.K. Melson, J.A. Schweiger, B.P. Cooper, and et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia Arch. Gen. Psychiatry 59 2002 337 345
77. D.W. Haupt, and J.W. Newcomer Hyperglycemia and antipsychotic medications J. Clin. Psychiatry 62 Suppl. 27 2001 15 26
78. L.L. Lipscombe, L. Levesque, A. Gruneir, H.D. Fischer, D.N. Juurlink, S.S. Gill, and et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes Arch. Intern. Med. 169 2009 1282 1289
79. C.M. Feek, J.S. Bevan, S. Taylor, N.S. Brown, and J.D. Baird The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly Clin. Endocrinol. (Oxf.) 15 1981 473 478
80. N. Ben Jonathan, E.R. Hugo, T.D. Brandebourg, and C.R. LaPensee Focus on prolactin as a metabolic hormone Trends Endocrinol. Metab. 17 2006 110 116
81. B. Le Foll, A. Gallo, Y. Le Strat, L. Lu, and P. Gorwood Genetics of dopamine receptors and drug addiction: a comprehensive review Behav. Pharmacol. 20 2009 1 17
82. B. Guigas, J.E. de Leeuw van Weenen, N. van Leeuwen, A.M. Simonis-Bik, T.W. van Haeften, G. Nijpels, and et al. Sex-specific effects of naturally occurring variants in the dopamine receptor D2 locus on insulin secretion and type 2 diabetes susceptibility Diabet. Med. 31 2014 1001 1008
83. R.I. Holt, and A.J. Mitchell Diabetes mellitus and severe mental illness: mechanisms and clinical implications Nat. Rev. Endocrinol. 11 2015 79 89
84. S.C. Gough, and M.C. O'Donovan Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J. Psychopharmacol. 19 2005 47 55
85. Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci Nature 511 2014 421 427
86. P.I. Lin, and A.R. Shuldiner Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes Schizophr. Res. 123 2010 234 243
87. C.P. Jenkinson, R. Hanson, K. Cray, C. Wiedrich, W.C. Knowler, C. Bogardus, and et al. Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians Int. J. Obes. Relat. Metab. Disord. 24 2000 1233 1238
88. M. Chiba, S. Suzuki, Y. Hinokio, M. Hirai, Y. Satoh, A. Tashiro, and et al. Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder Metabolism 49 2000 1145 1149
89. A.H. Cincotta, A.H. Meier, Therapeutic process for the treatment of the pathologies of type II diabetes, [US5866584] (1999). Ref type: Patent.
90. A.H. Cincotta, J.M. Cincotta, C.L. Pelloni, C.E. Runice, S.L. Tigner, Accelerated release composition containing bromocriptine, [US5679685] EP1258245A3 2003 (1997). Ref Type: Patent.
91. L. Moro, A. Fiori, A. Natali, Processes for the preparation of pharmaceutical compositions containing bromocriptine having high stability and related products, EP0391374 1994 (1991). Ref type: Patent.
92. A.J. Garber, L. Blonde, Z.T. Bloomgarden, Y. Handelsman, and S. Dagogo-Jack The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations Endocr. Pract. 19 2013 100 106
93. A.H. Cincotta, and A.H. Meier Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects Diabetes Care 19 1996 667 670
94. B. Chamarthi, J.M. Gaziano, L. Blonde, A. Vinik, R.E. Scranton, M. Ezrokhi, and et al. Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus J. Diabetes Res. 2015 2015 157698
95. P.W. Scislowski, E. Tozzo, Y. Zhang, S. Phaneuf, R. Prevelige, and A.H. Cincotta Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists Int. J. Obes. Relat. Metab. Disord. 23 1999 425 431
96. W. Liang, L. Gao, N. Li, B. Wang, L. Wang, Y. Wang, and et al. Efficacy and safety of bromocriptine-QR in type 2 diabetes: a systematic review and meta-analysis Horm. Metab. Res. 47 2015 805 812
97. P.R. Atkison, J.L. Mahon, J. Dupre, C.R. Stiller, M.R. Jenner, T.L. Paul, and et al. Interaction of bromocriptine and cyclosporine in insulin dependent diabetes mellitus: results from the Canadian open study J. Autoimmun. 3 1990 793 799